Lyra Therapeutics (LYRA) Gains from Investment Securities (2019 - 2025)
Quarterly Gains from Investment Securities rose 100.43% to $57716.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57716.0 through Dec 2025, up 100.43% year-over-year, with the annual reading at $57716.0 for FY2025, 54.29% down from the prior year.
Lyra Therapeutics' Gains from Investment Securities history spans 7 years, with the latest figure at $57716.0 for Q4 2025.
- Gains from Investment Securities came in at $57716.0 for Q4 2025, down from $68558.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $7.0 million in Q2 2024 to a low of -$13.6 million in Q4 2024.
- The 5-year median for Gains from Investment Securities is $435594.5 (2021), against an average of $268563.4.
- Year-over-year, Gains from Investment Securities soared 61577.1% in 2021 and then crashed 2253.49% in 2024.
- Lyra Therapeutics' Gains from Investment Securities stood at $1.9 million in 2021, then tumbled by 97.68% to $42879.0 in 2022, then surged by 1369.25% to $630000.0 in 2023, then plummeted by 2253.49% to -$13.6 million in 2024, then surged by 100.43% to $57716.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Gains from Investment Securities are $57716.0 (Q4 2025), $68558.0 (Q3 2025), and $3.0 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 57,716.00 |
| Dec 31, 2025 | 57,716.00 |
| Sep 30, 2025 | 68,558.00 |
| Sep 30, 2025 | 68,558.00 |
| Mar 31, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -13.57 Mn |
| Dec 31, 2024 | -13.57 Mn |
| Jun 30, 2024 | 7.05 Mn |
| Jun 30, 2024 | 7.05 Mn |
| Mar 31, 2024 | 385,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 630,000.00 |
| Dec 31, 2023 | 630,000.00 |
| Sep 30, 2023 | 431,489.00 |
| Sep 30, 2023 | 431,489.00 |
| Jun 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 1.98 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Mar 31, 2022 | 42,879.00 |
| Mar 31, 2022 | 42,879.00 |
| Sep 30, 2021 | 1.85 Mn |
| Sep 30, 2021 | 1.85 Mn |
| Jun 30, 2021 | 439,700.00 |
| Jun 30, 2021 | 439,700.00 |
| Mar 31, 2021 | 1,590.00 |
| Mar 31, 2021 | 1,590.00 |
| Sep 30, 2020 | 3,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Mar 31, 2020 | 901,678.00 |
| Mar 31, 2020 | 901,678.00 |
| Dec 31, 2019 | 125,000.00 |
| Dec 31, 2019 | 125,000.00 |
| Sep 30, 2019 | 23,000.00 |
| Sep 30, 2019 | 23,000.00 |
| Mar 31, 2019 | 4.05 Mn |
| Mar 31, 2019 | 4.05 Mn |